Last reviewed · How we verify
NCT06846021
Integral Single-cell Landscape of Immunological Hallmarks for Ankylosing Spondylitis
NA trial testing Disease status in Ankylosing Spondylitis in 17 participants. Completed in 25 August 2021.
30 June 2021
Quick facts
| Lead sponsor | Fujian Provincial Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 17 |
| Start date | 17 May 2021 |
| Primary completion | 30 June 2021 |
| Estimated completion | 25 August 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- Disease status
Conditions studied
- Ankylosing Spondylitis — all drugs for Ankylosing Spondylitis →
Sponsor
Fujian Provincial Hospital
Who can join
Eligibility, any sex, with Ankylosing Spondylitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Three HLA-B27-positive health donors (HDs) with matching age were enrolled via genetic screening, and fourteen AS patients were recruited at Fujian provincial hospital from May to July 2021. All AS patients satisfied the modified New York (NY) criteria, and the categorization of three disease groups (EA, LD and RM) was according to clinical hallmarks and imaging evidences. The five patients in the EA group were in the early stage of disease, showing obvious symptoms, and had not yet received standard treatments, including various NSAIDs and DMARDs. The five patients in the LD group were all disabled, and confirmed by radiographic evidence of structural damage in hip joints and spinal deformity. The four patients in the RM group received standardized treatment under the guidance of specialist doctors, and maintained clinical remission and normal laboratory indicators for over six months. Patients in both EA and RM groups were confirmed to have no structural damage or deformities by radiographic evidences.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06846021
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Disease status
Trials testing the same drug.
- NCT03437798 — Genomic Determinants and Shared Genetic Pathways of Periodontal Disease · completed
Other recruiting trials for Ankylosing Spondylitis
Currently open trials in the same condition.
- NCT07510789 — Impact of Low Back Pain Phenotypes on Function and Quality of Life in Ankylosing Spondylitis · recruiting
- NCT07261644 — A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS) · Phase 3 · recruiting
- NCT07390929 — Clinical Trial Study on the Improved New Method of Acupotomy for AS · NA · recruiting
- NCT06905288 — Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea. · recruiting
- NCT07166874 — The Impacts of Gluten-free Diet in Patients With Ankylosing Spondylitis · NA · recruiting
Other Fujian Provincial Hospital trials
Trials by the same sponsor.
- NCT07471763 — Prospective Lifespan Cohort of Myocardial Infarction · not yet recruiting
- NCT07290764 — Survival Analysis of Surgical Resection Versus Observation in Patients With Initially uHCC Achieving CR After Systemic T · enrolling by invitation
- NCT07251114 — AI-assisted Endoscopic Ultrasound Grading of Early Esophageal Cancer Invasion Depth: A Multicenter, Prospective, Randomi · NA · recruiting
- NCT06564506 — Electroacupuncture for Preventing Postoperative Delirium in Older Adults Undergoing Total Knee Arthroplasty · NA · not yet recruiting
- NCT07380542 — Dynamic Magnesium Replacement Strategies and 28-Day Mortality in Non-Cardiac Critically Ill Patients With Hypomagnesemia · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06846021 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fujian Provincial Hospital
- Last refreshed: 4 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06846021.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing